AIDS Weekly back issues from September 2002:
Drug eruption study yields surprising results.(drug allergy study)
Sep 02, 2002 ... 2002 SEP 2 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in France have shed new light on the inflammatory drug reactions often seen in HIV patients. "Persons with HIV infection have increased rates of drug eruptions," explained Muriel ...
Short-course nevirapine doesn't improve standard preventive therapy.
Sep 02, 2002 ... 2002 SEP 2 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Short-course nevirapine therapy doesn't help prevent vertical HIV transmission from women with access to standard treatment regimens, researchers argue. "A 2-dose intrapartum/newborn nevirapine ...
UCSD study shows increased transmission of drug-resistant HIV infection.
Sep 02, 2002 ... 2002 SEP 2 - (NewsRx.com & NewsRx.net) -- An increase in the transmission rate of drug-resistant HIV, now affecting as many as one in five newly infected people, has been discovered by researchers at the University of California, San Diego (UCSD) School of Medicine. In a 5-year, ...
Viral Nef protein triggers podocyte growth and proliferation.(of HIV-associated nephropathy)
Sep 02, 2002 ... 2002 SEP 2 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - The HIV Nef protein appears to be involved in the development of HIV-associated nephropathy (HIVAN), researchers say. "HIV-1 infection induces the loss of podocyte differentiation markers and ...
Novel technique enables single-cell latency analysis.
Sep 02, 2002 ... 2002 SEP 2 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in the United States have developed a novel technique for studying latent HIV infection. "The ability of human immunodeficiency virus type 1 (HIV-1) to establish latent infections in ...
T-20 administration has little impact on daily activities of patients after 8 weeks of treatment.
Sep 02, 2002 ... 2002 SEP 2 - (NewsRx.com & NewsRx.net) -- Roche and Trimeris, Inc., (TRMS) announced that data collected from a survey of patients in two large, internationally conducted phase III trials suggest that subcutaneous delivery of T-20 was well-accepted by a majority of patients after the first ...
Vietnam reports 9000 new people detected as HIV-positive.(Brief Article)
Sep 02, 2002 ... 2002 SEP 2 - (NewsRx.com & NewsRx.net) -- Just over 9000 new cases of HIV infection were logged in Vietnam during the first 7 months of this year, bringing the total number of HIV carriers in the country to more than 50,000, official media reported August 1, 2002. The 9024 ...
Young people account for 40% of HIV-infected in Japan.
Sep 02, 2002 ... 2002 SEP 2 - (NewsRx.com & NewsRx.net) -- People in their teens and 20s account for nearly 40% of all Japanese newly infected with the AIDS virus, according to new Health Ministry figures that officials say underline a disturbing new trend. While the overall number of Japanese ...
Once-daily HIV Medications pave way for simplified combination drug regimens.(Brief Article)
Sep 02, 2002 ... 2002 SEP 2 - (NewsRx.com & NewsRx.net) -- A once-daily drug regimen comprising three leading anti-HIV medications may allow HIV patients, who previously followed complicated, multidose drug regimens, to create a once-daily combination therapy to reduce the frequency of dosing of their HIV ...
Panacos unveils the leading compound in a new class of HIV drug candidates: budding inhibitors.(Panacos Pharmaceuticals Inc.)(Brief Article)
Sep 02, 2002 ... 2002 SEP 2 - (NewsRx.com & NewsRx.net) -- Panacos Pharmaceuticals, Inc., made its first public presentation on the company's HIV drug candidate, PA-457, at the XIV International AIDS Conference in Barcelona, Spain. PA-457 is the first in a new class of drug candidates known as ...
Roche, Trimeris announce next steps in bringing Fuzeon (T-20) to HIV patients.(Brief Article)
Sep 02, 2002 ... 2002 SEP 2 - (NewsRx.com & NewsRx.net) -- Results from Fuzeon (T-20) phase III studies, reported at the International AIDS Conference in Barcelona, showed greater than expected benefit in the patient population studied. In addition, the studies demonstrate better adherence to ...
Sarawak initiates clinical trial of Calanolide A in combination therapy for HIV.(Sarawak MediChem Pharmaceuticals Inc.)(Brief Article)
Sep 02, 2002 ... 2002 SEP 2 - (NewsRx.com & NewsRx.net) -- Sarawak MediChem Pharmaceuticals, Inc., announced that it has begun screening volunteers for a 48 subject, clinical trial of Calanolide A in combination therapy for HIV. This clinical trial will evaluate the therapy's safety and ...
Serono announces significant results from two clinical trials of Serostim.(Brief Article)
Sep 02, 2002 ... 2002 SEP 2 - (NewsRx.com & NewsRx.net) -- Serono S.A. (SRA) announced positive results of two major clinical trials of Serostim [somatropin (rDNA origin) for injection] for the treatment of AIDS-related metabolic complications at the XIV International AIDS Conference in Barcelona, Spain. ...
Sustiva provides immunosuppressed HIV/AIDS patients effective treatment alternative.
Sep 02, 2002 ... 2002 SEP 2 - (NewsRx.com & NewsRx.net) -- Data presented at the XIV International AIDS Conference show that a greater proportion of patients on highly active antiretroviral therapy (HAART) containing Sustiva (efavirenz), Bristol-Myers Squibb's (BMY) once-daily non-nucleoside reverse ...
FDA advisers plug new drug.(adefovir from Gilead Sciences Inc. for the treatment of hepatitis B)
Sep 02, 2002 ... 2002 SEP 2 - (NewsRx.com & NewsRx.net) -- A failed HIV therapy should be sold instead to treat the liver-destroying hepatitis B virus, advisers to the U.S. Food and Drug Administration have ruled. If the FDA agrees, Gilead Sciences' adefovir would become the first new treatment ...
The Immune Response Corp. announces proposed private offering of common stock and warrants.(Brief Article)
Sep 02, 2002 ... 2002 SEP 2 - (NewsRx.com & NewsRx.net) -- The Immune Response Corp. (MNR) announced it is seeking to raise, subject to market and other conditions, up to $8 million in gross proceeds ($10.4 million if the 30% overallotment option is exercised) through a private offering of units comprising ...
Texas medical center recalls body parts that were not tested for HIV, other infections.(University of Texas Medical Branch)
Sep 02, 2002 ... 2002 SEP 2 - (NewsRx.com & NewsRx.net) -- A medical center whose handling of cadavers has come under FBI investigation said August 6, 2002, that it is recalling body parts sent to research institutions around the country, warning they may carry the AIDS virus or other infections. ...
Gender, AIDS status do not affect isoniazid levels.
Sep 02, 2002 ... 2002 SEP 2 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in the United States have shed new light on the pharmacokinetics of a popular antituberculosis agent. John E. Conte Jr. and colleagues at the University of California in San Francisco ...
Alcohol use, thrill-seeking prove bad mix for HIV-positive men.
Sep 09, 2002 ... 2002 SEP 9 - (NewsRx.com & NewsRx.net) -- HIV-positive men who seek new experiences and think alcohol improves sex are more likely to have unprotected sex, according to a new study. Most HIV prevention programs target risk-takers who are not already infected. Many of the same ...
Hip osteonecrosis incidence may be rising.
Sep 09, 2002 ... 2002 SEP 9 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Necrotic degeneration of hip bones is becoming increasingly common in patients infected with HIV, researchers warn. "Osteonecrosis has been reported to occur occasionally among HIV-infected ...
Hepatitis C, Epstein-Barr virus interactions have little impact on lymphoma risk.
Sep 09, 2002 ... 2002 SEP 9 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Interactions between hepatitis C and Epstein-Barr viruses have little effect on the risk of non-Hodgkin lymphoma in HIV patients, researchers in France argue. "Immortalization of B cells by ...
Novel nucleic acid tests suitable for large-scale HIV, hepatitis C blood donor screening.
Sep 09, 2002 ... 2002 SEP 9 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in the United States have developed a highly sensitive assay system for finding HIV or hepatitis C infection in blood. "Various nucleic acid assays have been developed and ...
Low-dose paclitaxel effective for high-risk Kaposi sarcoma patients.
Sep 09, 2002 ... 2002 SEP 9 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Paclitaxel therapy can help patients suffering from refractory Kaposi sarcoma, according to researchers in the United States. "Treatment options are limited for patients with advanced acquired ...
ACTG Clinical Trial: Remune alone stimulated stronger immune responses.(AIDS Clinical Trials Group )
Sep 09, 2002 ... 2002 SEP 9 - (NewsRx.com & NewsRx.net) -- The Immune Response Corp. (IMNR) announced that the Adult AIDS Clinical Trials Group of the National Institutes of Health presented new data at the XIV International AIDS Conference from a clinical trial designed to ascertain if the nonspecific ...
New compound may immobilize AIDS virus, certain radionuclides.(niobium heteropolyanions )
Sep 09, 2002 ... 2002 SEP 9 - (NewsRx.com & NewsRx.net) -- A compound that could potentially immobilize the AIDS virus or selectively extract radionuclides from nuclear wastes at various U.S. high-level storage sites has been developed by a researcher at Sandia National Laboratories who wasn't even looking ...
MedImmune announces three new executives.(Brief Article)
Sep 09, 2002 ... 2002 SEP 9 - (NewsRx.com & NewsRx.net) -- MedImmune, Inc., (MEDI) announced the appointment of Pamela J. Lupien as vice president, human resources, Edward T. Mathers as vice president, corporate development, and Lota S. Zoth as vice president and controller. "I am pleased with ...
SurgiLance renews contract with Professional HealthSales.
Sep 09, 2002 ... 2002 SEP 9 - (NewsRx.com & NewsRx.net) -- SurgiLance, Inc., has renewed an annual agreement with Professional HealthSales, Inc., (PHS) of Perkasie, Pennsylvania, in which PHS and its team of 30 representatives will continue to be SurgiLance's national sales organization. PHS ...
Study shows promise for identifying lead compounds.
Sep 09, 2002 ... 2002 SEP 9 - (NewsRx.com & NewsRx.net) -- A recent study published in Nature Biotechnology has demonstrated a new method for identifying lead compounds for drug discovery. The method described in the study is based on technology developed by Tutzing, Germany-based biotechnology ...
VaxGen releases second-quarter results; development expenses met expectations.
Sep 09, 2002 ... 2002 SEP 9 - (NewsRx.com & NewsRx.net) -- VaxGen, Inc., (VXGN) announced a net loss of $6.7 million, or 46 cents per share excluding noncash charges, for the second quarter ended June 30, 2002, compared with a net loss of $5.9 million, or 42 cents per share excluding noncash charges, in ...
CDC visit to San Francisco probes workshops.(U.S. Centers for Disease Control and Prevention evaluates California city's public health program)
Sep 09, 2002 ... 2002 SEP 9 - (NewsRx.com & NewsRx.net) -- Federal officials met with members of San Francisco's public health department August 13, 2002, to try to determine whether HIV prevention workshops such as "A Walk on the Wildside" and "Guy Watch" are obscene. It's the second time in ...
California representatives cross party lines to back increase for AIDS drugs.
Sep 09, 2002 ... 2002 SEP 9 - (NewsRx.com & NewsRx.net) -- California's representatives in Congress joined across party lines to ask House of Representatives leadership to end waiting lists for AIDS drugs by increasing funds for treatment. "With over 1200 uninsured Americans on waiting lists for ...
Patients with bleeding disorder face liver disease from bloodborne pathogens.
Sep 09, 2002 ... 2002 SEP 9 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - The cumulative incidence of hepatitis C virus (HCV)-related end-stage liver disease in patients with hemophilia increases with human immunodeficiency virus (HIV) coinfection, according to a report from the ...
Human herpesvirus-8 infection common in south Texas children.
Sep 09, 2002 ... 2002 SEP 9 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Young children in south Texas have a surprisingly high risk of infection with a cancer-causing virus, researchers warn. "Human herpesvirus 8 (HHV-8), also known as Kaposi's sarcoma-associated ...
AIDS activists threaten legal action if government rejects critical AIDS drug.(nevirapine )
Sep 09, 2002 ... 2002 SEP 9 - (NewsRx.com & NewsRx.net) -- AIDS activists have threatened to sue the South African body that regulates medicines if it withdraws its approval of a drug used to help stop the spread of HIV from pregnant women to their babies. South Africa's Medicines Control ...
Elizabeth Glaser Pediatric AIDS Foundation awarded $100M.
Sep 09, 2002 ... 2002 SEP 9 - (NewsRx.com & NewsRx.net) -- The Elizabeth Glaser Pediatric AIDS Foundation announced that the United States Agency for International Development (USAID) has awarded a grant of up to $100 million over 5 years to the Foundation's international Call to Action Project, which is ...
De Beers becomes latest company to make AIDS drugs available to its employees.(Brief Article)
Sep 09, 2002 ... 2002 SEP 9 - (NewsRx.com & NewsRx.net) -- With a swipe at South Africa's often-criticized AIDS policy, diamond giant De Beers announced August 12, 2002, it would heavily subsidize the cost of AIDS medicine for its employees. The announcement made De Beers the latest major ...
RNA interference could be effective treatment strategy.
Sep 16, 2002 ... 2002 SEP 16 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in the United States have identified a novel and promising treatment modality against HIV infection. "Synthetic small interfering RNAs (siRNAs) have been shown to induce the ...
Genotyping less effective at predicting effective regimens in children.
Sep 16, 2002 ... 2002 SEP 16 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - A commonly used method of determining appropriate HIV treatment for adults may not work as well for pediatric HIV patients, researchers in the United States warn. "HIV genotyping has been ...
Promising multistrain HIV vaccine candidate emerges.
Sep 16, 2002 ... 2002 SEP 16 - (NewsRx.com & NewsRx.net) -- AIDS researchers have developed a candidate vaccine strategy that, for the first time, demonstrates an ability to elicit antibodies that block the infection of multiple HIV virus strains - an elusive scientific goal that has been pursued for a ...
Substance P blocker can prevent viral replication.(HIV replication)
Sep 16, 2002 ... 2002 SEP 16 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in the United States have identified a novel agent that shows promise as a treatment for HIV and other viral infections. "Substance P (SP), a potent modulator of ...
T-20 safe, effective for pediatric use.(HIV treatment for children)
Sep 16, 2002 ... 2002 SEP 16 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - The novel anti-HIV agent T-20 is safe and effective for use with infected children, researchers in the United States say. "Entry inhibitors, a new class of antiretroviral agents, interfere with ...
Twenty years of monkey research boosts AIDS knowledge.
Sep 16, 2002 ... 2002 SEP 16 - (NewsRx.com & NewsRx.net) -- Research on an AIDS-like disease in monkeys continues to help scientists understand problems such as how HIV causes AIDS, how the virus "hides" from the immune system and how the disease might be prevented or treated, two decades after the human ...
HIV targets active genes in cells.
Sep 16, 2002 ... 2002 SEP 16 - (NewsRx.com & NewsRx.net) -- HIV selectively inserts itself into active areas of a host cell's genome, Salk Institute researchers have found for the first time. The fact that the virus hooks itself up to areas of the cell's genome that are busy expressing ...
New drug raises hopes, fears.(Fuzeon fusion inhibitor for HIV treatment)
Sep 16, 2002 ... 2002 SEP 16 - (NewsRx.com & NewsRx.net) -- The U.S. government has approved tests of an experimental and potentially expensive AIDS drug that could prolong the lives of patients with drug-resistant strains of HIV. Dubbed Fuzeon by its developers, Roche Group and Trimeris, Inc., ...
The Immune Response Corp. announces results from Remune trial.
Sep 16, 2002 ... 2002 SEP 16 - (NewsRx.com & NewsRx.net) -- Indicating for the first time in a clinical trial that Remune might give relief for HIV-infected patients from the adverse side-effects of antiretroviral therapies, The Immune Response Corp. (IMNR) announced results from an ongoing study by the ...
Groundbreaking approach to prevent transmission of HIV shows promise.(microbicides )
Sep 16, 2002 ... 2002 SEP 16 - (NewsRx.com & NewsRx.net) -- New, anti-infective substances that can be developed as gels, creams, foams, films, even impregnated sponges and suppositories may prove to be a ground-breaking approach to preventing the spread of HIV, the virus that causes AIDS, according to an ...
Calypte receives initial order for urine HIV tests from West Africa.(Calypte Biomedical Corp. )
Sep 16, 2002 ... 2002 SEP 16 - (NewsRx.com & NewsRx.net) -- Calypte Biomedical Corporation (CALY), the developer and marketer of the only two FDA-approved HIV-1 Antibody tests that can be used on urine samples announced that it has received its first West African order. The order calls for ...
Hepatitis worse during immunocompetence with HIV/hepatitis C coinfection.
Sep 16, 2002 ... 2002 SEP 16 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - Ironically, liver disease may worsen when there is immunocompetence in hemophiliacs coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Medical investigators in ...
Roche Molecular initiates trials of Cobas AmpliScreen HBV test.(hepatitis B test)
Sep 16, 2002 ... 2002 SEP 16 - (NewsRx.com & NewsRx.net) -- Roche Molecular Systems, Inc., (Roche) announced the start of comprehensive clinical trials of its Cobas AmpliScreen HBV test. The trials mark an important milestone because, for the first time in the U.S., Roche's PCR nucleic acid ...
Group wins $127M for global health communication project.
Sep 16, 2002 ... 2002 SEP 16 - (NewsRx.com & NewsRx.net) -- A group led by the Johns Hopkins University Center for Communication Programs (JHU/CCP) has been awarded $127 million by the U.S. government to implement a 5-year global project designed to use strategic communication to fight infectious diseases ...
Liquid efavirenz safe, effective for children.(with HIV infection)
Sep 16, 2002 ... 2002 SEP 16 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - A liquid version of the powerful antiretroviral agent efavirenz is safe and effective for pediatric use, researchers say. Stuart E. Starr and colleagues at the Children's Hospital of ...
Head of World Summit: Development progress impossible without tackling AIDS.
Sep 16, 2002 ... 2002 SEP 16 - (NewsRx.com & NewsRx.net) -- Progress in global development is impossible without tackling the AIDS pandemic, the head of the World Summit said August 25, 2002. Fighting the disease is a major objective of the 10-day gathering that started August 26, said Nitin ...
Controversial rapid screen effective after occupational exposure.
Sep 23, 2002 ... 2002 SEP 23 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - A controversial rapid HIV test can be effectively used to screen for infection after occupational exposure, researchers in Virginia argue. "The Single Use Diagnostic System (SUDS) HIV-1 Test is ...
Arginine treatment may improve immune function.
Sep 23, 2002 ... 2002 SEP 23 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Treatment with the nonessential amino acid arginine may improve immune function in HIV patients, researchers in the United States report. Dr. Barbara Swanson and colleagues at Rush University in ...
Significantly improved survival in intensive care seen for HIV patients.
Sep 23, 2002 ... 2002 SEP 23 - (NewsRx.com & NewsRx.net) -- A patient infected with human immunodeficiency virus (HIV) who is admitted to the intensive care unit (ICU) in this era of highly active antiretroviral therapy has a markedly improved survival rate, according to a study in the first issue for ...
Lopinavir and ritonavir superior to nelfinavir-based regimens.
Sep 23, 2002 ... 2002 SEP 23 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - A group of researchers have shed new light on the relative efficacies of several antiretroviral agents used to treat HIV infection. "Lopinavir is a newly developed inhibitor of human ...
Murabatide safely improves immune response to infection.
Sep 23, 2002 ... 2002 SEP 23 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - A novel agent can greatly enhance the immune response to HIV infection, researchers in France say. "The safe synthetic immunomodulator Murabutide (ISTAC Biotechnology, Lille, France) has been ...
Cosmetic surgery can restore facial appearance.
Sep 23, 2002 ... 2002 SEP 23 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Cosmetic surgery can be used to flesh out the gaunt appearance associated with HIV lipodystrophy, researchers say. "The use of highly active antiretroviral therapy (HAART) with protease ...
Manufacturer says Chinese version of anti-AIDS drug to reach patients by end of year.(Brief Article)
Sep 23, 2002 ... 2002 SEP 23 - (NewsRx.com & NewsRx.net) -- A generic version of the anti-AIDS drug AZT will be available in China before the end of the year as a low-cost alternative to pricey imported medicines, the manufacturer said August 16, 2002. Northeast Pharmaceutical Group, based in ...
Norzyme awarded grant by National Institutes of Health.
Sep 23, 2002 ... 2002 SEP 23 - (NewsRx.com & NewsRx.net) -- Norzyme, Inc., developers of in vitro diagnostic technology for therapeutic drug monitoring, announced the National Institutes of Health (NIH) has further recognized the promise of its Levoprin-ZG product to aid in the disease management of ...
Orathecin receives orphan-drug designation for treatment of pediatric AIDS.(Brief Article)
Sep 23, 2002 ... 2002 SEP 23 - (NewsRx.com & NewsRx.net) -- SuperGen, Inc., (SUPG) announced that its oral anticancer cancer compound Orathecin has received orphan-drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of pediatric patients infected with human immunodeficiency ...
Roche and Trimeris open physician enrollment for Fuzeon early access program.(Brief Article)
Sep 23, 2002 ... 2002 SEP 23 - (NewsRx.com & NewsRx.net) -- Roche and Trimeris (TRMS) announced that physician enrollment for the U.S. early-access program for Fuzeon (enfuvirtide), formerly known as T-20, opened on August 19, 2002. This program, running parallel with other controlled Fuzeon ...
Triangle Pharmaceuticals names Daniel G. Welch chairman and CEO.(Brief Article)
Sep 23, 2002 ... 2002 SEP 23 - (NewsRx.com & NewsRx.net) -- Triangle Pharmaceuticals, Inc., (VIRS) announced that Daniel G. Welch has been appointed chairman and CEO effective August 5, 2002. Welch succeeds Dr. David Barry, founder and former chief executive officer, who died in January 2002. ...
VaxGen joint venture to buy 24 acres in South Korea.(Brief Article)
Sep 23, 2002 ... 2002 SEP 23 - (NewsRx.com & NewsRx.net) -- VaxGen, Inc., (VXGN) announced that its biopharmaceutical manufacturing joint venture, Celltrion, Inc., has secured the purchase of 24-acres of land in Incheon, South Korea, for the site of its major biologics manufacturing facility. ...
ViroLogic: Data on increase in HIV drug resistance published.
Sep 23, 2002 ... 2002 SEP 23 - (NewsRx.com & NewsRx.net) -- ViroLogic, Inc., (VLGC) announced that the spread of drug-resistant HIV has accelerated rapidly over the last several years according to research using its technology and published in the New England Journal of Medicine. Drug-resistant viruses ...